QUOTE AND NEWS
GenEng News  May 27  Comment 
Halozyme Therapeutics said today it will co-develop a companion diagnostic for its cancer drug candidate PEGPH20 with Ventana Medical Systems, a member of the Roche Group. The value of the collaboration was not disclosed. Ventana will...
Benzinga  May 18  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has developed a new drug called PEGPH 20, which is changing the way pancreatic cancer patients are treated. Helen Torley, Halozyme Therapeutics CEO, was on CNBC Monday to shed more light on the drug and...
Forbes  May 8  Comment 
Halozyme Therapeutics is expected to book a narrower loss than a year ago when it reports first-quarter earnings on Monday, May 11, 2015. Analysts are expecting a loss of 13 cents per share, up from a loss of 22 cents per share a year...
Benzinga  Apr 8  Comment 
In a report published Wednesday, MLV & Co analysts maintained a Buy rating for Halozyme Therapeutics, Inc (NASDAQ: HALO), with a price target of $20. Following a meeting with the FDA in 1Q15, the company has now announced its plans to commence...
Benzinga  Apr 8  Comment 
Shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) opened higher Wednesday following an update on meetings with the FDA. According to the company's press release, it "plans to proceed with a Phase 3 clinical study (Study 301) of its...
Benzinga  Mar 2  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) posted better-than expected fourth quarter results on Monday, but offered a revenue forecast shy of analysts' consensus. The San Diego-based drug development company changed hands recently in the...
Forbes  Feb 27  Comment 
Halozyme Therapeutics is expected to book a narrower loss than a year ago when it reports fourth-quarter earnings on Monday, March 2, 2015. Analysts are expecting a loss of nine cents per share, up from a loss of 19 cents per share a year ago.The...
Benzinga  Jan 8  Comment 
Neurocrine Biosciences Inc. (NASDAQ: NBIX) surged 21.07% to $26.49. The volume of Neurocrine Biosciences shares traded 1407% higher than normal. AbbVie Inc. (NYSE: ABBV), in cooperation with Neurocrine Biosciences, announced positive top-line...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki